# CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

> **NCT06035744** · PHASE1 · RECRUITING · sponsor: **Cullinan Therapeutics Inc.** · enrollment: 86 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** CLN-617
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06035744
- **Lead sponsor:** Cullinan Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-12
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06035744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06035744, "CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06035744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*